Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
TYO: 4502
Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...
Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals
The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...
Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment
Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...
Takeda’s Obizur Accepted by China’s NMPA for Acquired Hemophilia A Treatment
Takeda Pharmaceutical Co., Ltd’s (NYSE: TAK, TYO: 4502) China unit announced that a New Drug...